Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-PET/MRI for Radiation Planning in Prostate Cancer
NCT04086966Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2020
- Primary completion
- Feb 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by University of Alabama at Birmingham. Primary endpoint: The Number of Patients Who Demonstrate Pelvic Lymph Node Metastases on PSMA-PET/MRI That Were Not Detected on MRI. Started Aug 2020; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04086966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086966.